WO2005062788A3 - Prostate specific proteins expressed in cancer and methods of use thereof - Google Patents

Prostate specific proteins expressed in cancer and methods of use thereof Download PDF

Info

Publication number
WO2005062788A3
WO2005062788A3 PCT/US2004/042406 US2004042406W WO2005062788A3 WO 2005062788 A3 WO2005062788 A3 WO 2005062788A3 US 2004042406 W US2004042406 W US 2004042406W WO 2005062788 A3 WO2005062788 A3 WO 2005062788A3
Authority
WO
WIPO (PCT)
Prior art keywords
cancer
methods
disclosed
prostate specific
specific proteins
Prior art date
Application number
PCT/US2004/042406
Other languages
French (fr)
Other versions
WO2005062788A2 (en
Inventor
Bernd Weigle
Reinhard Ebner
Original Assignee
Avalon Pharmaceuticals
Bernd Weigle
Reinhard Ebner
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Avalon Pharmaceuticals, Bernd Weigle, Reinhard Ebner filed Critical Avalon Pharmaceuticals
Publication of WO2005062788A2 publication Critical patent/WO2005062788A2/en
Publication of WO2005062788A3 publication Critical patent/WO2005062788A3/en
Priority to US11/599,845 priority Critical patent/US20080025981A1/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57434—Specifically defined cancers of prostate

Abstract

Cancer-linked gene sequences, and derived amino acid sequences, are disclosed along with processes for assaying potential antitumor agents based on their modulation of the expression of these cancer-linked genes. Also disclosed are antibodies that react with the disclosed polypeptides and methods of using the antibodies to treat cancerous conditions, such as by using the antibody to target cancerous cells in vivo for purposes of delivering therapeutic agents thereto. Also described are methods of diagnosing using the gene sequences.
PCT/US2004/042406 2002-03-04 2004-12-16 Prostate specific proteins expressed in cancer and methods of use thereof WO2005062788A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US11/599,845 US20080025981A1 (en) 2002-03-04 2006-11-15 Cancer-linked genes as targets for chemotherapy

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US53180903P 2003-12-22 2003-12-22
US60/531,809 2003-12-22

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US10583832 A-371-Of-International 2004-12-16
US11/599,845 Continuation-In-Part US20080025981A1 (en) 2002-03-04 2006-11-15 Cancer-linked genes as targets for chemotherapy

Publications (2)

Publication Number Publication Date
WO2005062788A2 WO2005062788A2 (en) 2005-07-14
WO2005062788A3 true WO2005062788A3 (en) 2006-10-26

Family

ID=34738704

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2004/042406 WO2005062788A2 (en) 2002-03-04 2004-12-16 Prostate specific proteins expressed in cancer and methods of use thereof

Country Status (1)

Country Link
WO (1) WO2005062788A2 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2177630A1 (en) * 2008-10-02 2010-04-21 Institut Gustave Roussy Methods for predicting or monitoring whether a patient affected by a cancer is responsive to a treatment with a molecule of the taxoid family
WO2019040780A1 (en) 2017-08-25 2019-02-28 Five Prime Therapeutics Inc. B7-h4 antibodies and methods of use thereof
BR112020017925A2 (en) 2018-03-02 2020-12-22 Five Prime Therapeutics, Inc. ANTIBODIES AGAINST B7-H4 AND METHODS OF USE OF THE SAME

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004092213A1 (en) * 2003-04-08 2004-10-28 The Government Of The United States Of America As Represented By The Secretary, Department Of Healthand Human Services Gene expressed in prostate cancer, methods and use thereof

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004092213A1 (en) * 2003-04-08 2004-10-28 The Government Of The United States Of America As Represented By The Secretary, Department Of Healthand Human Services Gene expressed in prostate cancer, methods and use thereof

Also Published As

Publication number Publication date
WO2005062788A2 (en) 2005-07-14

Similar Documents

Publication Publication Date Title
WO2003097803A3 (en) Cancer-linked gene as target for chemotherapy
WO2003101400A3 (en) Cancer-linked gene as target for chemotherapy
WO2003105758A3 (en) Cancer-linked gene as target for chemotherapy
WO2003104399A3 (en) Cancer-linked gene as target for chemotherapy
WO2005047458A3 (en) Modified recombinant vaccina viruses and other microorganisms, uses thereof
WO2004113571A3 (en) Prostate specific genes and the use thereof as targets for prostate cancer therapy and diagnosis
WO2008020596A3 (en) Treating or preventing cancers over-expressing reg4 or kiaa0101
WO2002029086A3 (en) Nucleic acid sequences differentially expressed in cancer tissue
WO2003066663A3 (en) Peptides for recognition and targeting of glial cell tumors
WO2005062788A3 (en) Prostate specific proteins expressed in cancer and methods of use thereof
IL207012A0 (en) Diagnosis and therapy of cancer using sgp28-related molecules
WO2003076579A3 (en) Cancer-linked gene as target for chemotherapy
WO2003104401A3 (en) Cancer-linked gene as target for chemotherapy
WO2003104438A3 (en) Cancer-linked gene as target for chemotherapy
WO2005079490A3 (en) Methods of therapy and diagnosis using targeting of cells that express steap2 polypeptides
WO2002031198A3 (en) Cancer-linked genes as targets for chemotherapy
WO2003097802A3 (en) Cancer-linked gene as target for chemotherapy
WO2004058167A3 (en) Breast specific protein expressed in cancer and methods of use thereof
WO2003076587A3 (en) Cancer-linked gene as target for chemotherapy
WO2007013479A3 (en) Genes and polypeptides relating to prostate cancers
WO2003105783A3 (en) Cancer-linked gene as target for chemotherapy
WO2005017104A3 (en) Cancer-linked gene as target for chemotherapy
WO2003104404A8 (en) Cancer-linked gene as target for chemotherapy
WO2005002417A3 (en) Cancer -linked gene aas target for chemotherapy
WO2003097801A3 (en) Cancer-linked gene as target for chemotherapy

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DPEN Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed from 20040101)
NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Country of ref document: DE

122 Ep: pct application non-entry in european phase